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Background
Antiretroviral therapies against HIV infection reduce the
plasma viral load but can not eradicate the virus. Den-
dritic cells (DC) transfected with messenger ribonucleic
acids (mRNA) encoding endogenous viral proteins are
expected to enhance the HIV specific immune response
and are considered as potent therapeutic vaccines. In this
context we studied the feasibility and efficiency of mRNA
loaded CD34+ derived DC as therapeutic vaccine in SIV
infected macaques as a model of HIV infection and AIDS.
Methods
DC were derived from macaque medullar CD34+ cells by
in vitro proliferation for 7 days with early acting cytokines,
IL-3 and IL-6 and by differentiation for 7 days with GM-
CSF and IL-4. To mature the cells, a cocktail consisting of
pro-inflammatory cytokines was added for 24 hours.
Mature DC were transfected by electroporation with
human codon optimized HxB-2 Gag mRNA. Two hours
after electroporation, cells were frozen until use for vacci-
nation. In a preliminary study, uninfected animals
received 4 injections 4 weeks apart of 15 × 106 autologous
transfected DC, administered both intradermaly and sub-
cutaneously. Immunomonitoring was focused on the
detection of Gag-specific antibodies and IFN-γ and IL-2
secreting cells in peripheral blood.
Results
This process yielded 10 to 60 fold more DC than the input
number of CD34+ cells. The electroporated DC express
CD83, CCR7; high level of HLA-DR, CD40, CD86, CD1a,
CD1d, ASGPR and CLEC-6; and lower level of DC-SIGN,
Dectin-1, Lox-1 and DCIR. After thawing, 90% cells were
alive and 70% expressed Gag. Two weeks after the first
vaccination, peripheral blood cells evidenced strong pro-
duction of IFN-γ and IL-2. This indicated that it is possible
to induce polyfunctional T-cells.
Conclusion
This opens perspectives for the use of CD34+ derived DC
electroporated with mRNA encoding HIV-gag as therapeu-
tic vaccine in macaque model.
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